로딩 중…
지수 로딩 중…
NATURECELL CO.,LTD.
007390· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩29,050-5.22%
2026-06-19
Price Chart
NATURECELL CO.,LTD.+7.59%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 1.87T KRW |
| Revenue | 20.72B KRW |
| Net Income | -2.74B KRW |
| Total Assets | 86.75B KRW |
| Net Assets | 63.09B KRW |
| Employees | 91 |
| Value | |
| P/B | 29.67x |
| P/S | 90.35x |
| FCF Yield | -0.10% |
| Profitability | |
| ROE | -4.34% |
| ROA | -3.16% |
| Op. Margin | -15.75% |
| Revenue Growth | -0.44% |
| Earnings Growth | -1018.42% |
| Financial Health | |
| Debt Ratio | 137.50% |
| Total Debt | 17.00B KRW |
| FCF | -1.95B KRW |
| Cash | 28.34B KRW |
| Current Ratio | 1.94x |
| Performance | |
| 1Y Return | 7.59% |
| 1M Return | 61.03% |
| From 52W High | -26.18% |
| 1Y MDD | -55.29% |
| Trading | |
| Volume | 530,461 shares |
| Foreign Own. | 8.98% |
| Per Share | |
| EPS | -43 KRW |
| BPS | 979 KRW |
Company Info
Established in 1971 and listed on KOSDAQ in 1992, the company changed its corporate name to Naturecell Co., Ltd. in 2013, and acquired 100% of Naturecell America in the US in 2022, incorporating it as a subsidiary. It focuses on the R&D and commercialization of treatments for rare and intractable diseases using autologous fat-derived stem cells, conducting overseas clinical trials. Additionally, it manufactures and sells stem cell culture medium cosmetics and vegan beverages. Naturecell is headquartered in Yeongdeungpo-gu, Seoul.